Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs AXT Inc (AXTI) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs AXT Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while AXT Inc trades at $77.38 (market cap $4.83B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.1× AXT Inc's market cap, and AXT Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYAXTI
Market Cap
$29.60B$4.83B
Sector
HealthTechnology
52-Week High
$491.22$140.83
52-Week Low
$205.48$2.05
Enterprise Value
$27.56B$4.50B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

AXT Inc

AXTI trades at $79.75, up 8.05% on the day, reflecting strong momentum following Q2 2026 earnings that beat estimates with EPS of $0.19 versus $0.07 expected. The stock is in a bullish technical trend, with support near $72 and resistance at $79. Revenue surged to $126 million in 2026, driving a net profit of $4 million and margin expansion to 3.23%, supported by record indium phosphide demand for AI data centers.

Outlook is positive given AI-driven demand and capacity expansion, but high valuation ratios (P/S 30.53) and negative operating cash flow pose risks. Analyst consensus is bullish with a $72.50 price target, though the current price exceeds it, suggesting near-term consolidation may occur.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About AXT Inc

AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.

Read more on AXTI